Bernadette Reyna Asuncion
Overview
Explore the profile of Bernadette Reyna Asuncion including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choo J, Kua L, Soe M, Asuncion B, Tan B, Teo C, et al.
Gastric Cancer
. 2023 Feb;
26(3):393-404.
PMID: 36781556
Background: We evaluated the relevance of PD-1CD8 T-cells in gastric cancer (GC) including prognostic significance, association with chemotherapy and immunotherapy sensitivity and correlations with the tumor microenvironment (TME). Methods: Discovery...
2.
Mimura K, Kua L, Xiao J, Asuncion B, Nakayama Y, Syn N, et al.
Gastric Cancer
. 2021 Feb;
24(3):611-623.
PMID: 33611641
Background: Immunotherapy targeting PD-1 provides a limited survival benefit in patients with unresectable advanced or recurrent gastric cancer (GC). Beside PD-L1, the expression of inhibitory ligands such as CEACAM-1 and...
3.
Yong W, Rha S, Tan I, Choo S, Syn N, Koh V, et al.
Clin Cancer Res
. 2018 Jul;
24(21):5272-5281.
PMID: 30045931
The oxaliplatin plus S-1 and cisplatin plus S-1 regimens are interchangeably used in the management of advanced gastric cancer. The previously reported G-intestinal (G1) and G-diffuse (G2) intrinsic gene expression...
4.
Soo R, Lim J, Asuncion B, Fazreen Z, Herrera M, Omar M, et al.
Oncotarget
. 2018 Feb;
9(6):6841-6851.
PMID: 29467933
Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentially predictive of clinical outcome. The aim of this study was to assess the concordance of reported PD-L1 IHC...
5.
Soo R, Kim H, Asuncion B, Fazreen Z, Omar M, Herrera M, et al.
Lung Cancer
. 2017 Feb;
105:17-22.
PMID: 28236980
Objectives: To characterize the expression of PD-L1, PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and T-cell immunoglobulin and mucin-domain containing-3 (TIM3) in epidermal growth factor receptor (EGFR) mutant non-small cell lung...
6.
Sundar R, Jeyasekharan A, Pang B, Soong R, Kumarakulasinghe N, Ow S, et al.
PLoS One
. 2016 Oct;
11(10):e0164319.
PMID: 27716814
Introduction: Sensory peripheral neuropathy caused by paclitaxel is a common and dose limiting toxicity, for which there are currently no validated predictive biomarkers. We investigated the relationship between the Charcot-Marie-Tooth...
7.
Christoph D, Asuncion B, Hassan B, Tran C, Maltzman J, OShannessy D, et al.
J Thorac Oncol
. 2012 Dec;
8(1):19-30.
PMID: 23242435
Introduction: Folate receptor alpha (FRA) regulates cellular uptake of folates and antifolates. Information about FRA protein expression in metastatic non-small-cell lung cancer (NSCLC) is limited. We investigated FRA as a...
8.
Christoph D, Asuncion B, Mascaux C, Tran C, Lu X, Wynes M, et al.
J Thorac Oncol
. 2012 Aug;
7(9):1440-8.
PMID: 22895141
Background: Pemetrexed-based chemotherapy represents the standard of care in first-line treatment of advanced malignant pleural mesothelioma (MPM). However, there are no established predictors of clinical benefit. Pemetrexed inhibits multiple enzymes...
9.
Christoph D, Hoffmann A, Gauler T, Asuncion B, Loewendick H, Peglow A, et al.
J Thorac Oncol
. 2012 Mar;
7(4):766-7.
PMID: 22425929
No abstract available.
10.
Dziadziuszko R, Wynes M, Singh S, Asuncion B, Ranger-Moore J, Konopa K, et al.
J Thorac Oncol
. 2012 Jan;
7(2):340-7.
PMID: 22237262
Purpose: The MET receptor is involved in the pathogenesis and progression of non-small cell lung cancer (NSCLC). Clinical trials with MET inhibitors in NSCLC are planned with patient selection based...